Evidence map›Paper›PMID 39468660›Full record

ArticleStem cell research & therapy2024

Concurrent hypoxia and apoptosis imparts immune programming potential in mesenchymal stem cells: Lesson from acute graft-versus-host-disease model.

Mohini Mendiratta, Meenakshi Mendiratta, Shuvadeep Ganguly, Sandeep Rai, Ritu Gupta, Lalit Kumar, Sameer Bakhshi, Vatsla Dadhwal, Deepam Pushpam, Prabhat Singh Malik and 17 more

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Mohini MendirattaDepartment of Medical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
Meenakshi MendirattaStem Cell Facility (DBT-Centre of Excellence for Stem Cell Research), All India Institute of Medical Sciences, New Delhi, 110029, India.
Shuvadeep GangulyDepartment of Medical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
Sandeep RaiLaboratory Oncology Unit, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
Ritu GuptaLaboratory Oncology Unit, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
Lalit KumarDepartment of Medical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
Sameer BakhshiDepartment of Medical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
Vatsla DadhwalDepartment of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, 110029, India.
Deepam PushpamDepartment of Medical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
Prabhat Singh MalikDepartment of Medical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
Raja PramanikDepartment of Medical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
Mukul AggarwalDepartment of Hematology, All India Institute of Medical Sciences, New Delhi, 110029, India.
Aditya Kumar GuptaDepartment of Pediatric Oncology, All India Institute of Medical Sciences, New Delhi, 110029, India.
Rishi DhawanDepartment of Hematology, All India Institute of Medical Sciences, New Delhi, 110029, India.
Tulika SethDepartment of Hematology, All India Institute of Medical Sciences, New Delhi, 110029, India.
Manoranjan MahapatraDepartment of Hematology, All India Institute of Medical Sciences, New Delhi, 110029, India.
Baibaswata NayakDepartment of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, 110029, India.
Thoudam Debraj SinghDepartment of Medical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
Sachin KumarDepartment of Medical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
Riyaz Ahmed MirDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, 110029, India.
Gurvinder KaurLaboratory Oncology Unit, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
Hariprasad GuruRaoDepartment of Biophysics, All India Institute of Medical Sciences, New Delhi, 110029, India.
Mayank SinghDepartment of Medical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
Chandra Prakash PrasadDepartment of Medical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
Hridayesh PrakashAmity Centre for Translational Research, Amity University, Sector - 125, Noida, 201313, India. hprakash@amity.edu.
Sujata MohantyStem Cell Facility (DBT-Centre of Excellence for Stem Cell Research), All India Institute of Medical Sciences, New Delhi, 110029, India. drmohantysujata@gmail.com.
Ranjit Kumar SahooDepartment of Medical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India. drranjitmd@aiims.edu.

Funding

Indian Council of Medical Research 2021/14763
6 · The paper itself

Abstract

backgroundMesenchymal stem cells (MSCs) have emerged as promising candidates for immune modulation in various diseases that are associated with dysregulated immune responses like Graft-versus-Host-Disease (GVHD). MSCs are pleiotropic and the fate of MSCs following administration is a major determinant of their therapeutic efficacy.

methodsHuman MSCs were derived from bone marrow (BM) and Wharton's Jelly (WJ) and preconditioned through exposure to hypoxia and induction of apoptosis, either sequentially or simultaneously. The immune programming potential of preconditioned MSCs was evaluated by assessing their effects on T cell proliferation, induction of Tregs, programming of effector T-cell towards Th2 phenotype, macrophage polarization in the direct co-culture of MSCs and aGVHD patients-derived PBMNCs. Additionally, efferocytosis of MSCs and relative change in the expression of immunomodulatory soluble factors were examined.

resultsOur study demonstrated that hypoxia preconditioned apoptotic MSCs (BM-MSCs, WJ-MSCs) bear more immune programming ability in a cellular model of acute Graft-versus-Host-Disease (aGVHD). Our findings revealed that WJ-MSCs

conclusionOur study highlights the potential of WJ-MSCs conditioned with hypoxia and apoptosis concurrently, as a promising therapeutic strategy for aGVHD. It underscores the importance of considering MSC apoptosis in optimizing MSCs-based cellular therapy protocols for enhanced therapeutic efficacy in aGvHD.

Indexed as

ApoptosisGraft vs Host DiseaseMesenchymal Stem CellsAdultCell DifferentiationCell HypoxiaCell ProliferationCells, CulturedCoculture TechniquesFemaleHumansMacrophagesMaleT-Lymphocytes, RegulatoryAcute graft-versus-host-diseaseApoptosisBone marrowHypoxiaImmunomodulationMesenchymal stem cellsWharton’s Jelly

Identifiers

PMID39468660
PMCPMC11520827

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.